A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE004 (DEU) · Dr. Tanaka
consented 2023-03-22
Adverse events
Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-05-20 (study day 47); relationship: not assessed
Grade 2 Aspartate aminotransferase increased — outcome: RECOVERED/RESOLVED; onset 2023-05-24 (study day 51); relationship: not assessed
Grade 2 Colitis — outcome: RECOVERED/RESOLVED; onset 2023-07-25 (study day 113); relationship: not assessed
Grade 3 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-10-28 (study day 208); relationship: Y
Grade 3 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-12-19 (study day 260); relationship: not assessed
Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2024-02-10 (study day 313); relationship: not assessed
Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2024-07-03 (study day 457); relationship: not assessed
Data queries
No data queries.